Compare Biogen Inc (BIIB) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Live Nation Entertainment, Inc. — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Live Nation Entertainment, Inc. trades at $183.14 (market cap $42.71B). The key difference: Live Nation Entertainment, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| BIIB | LYV | |
|---|---|---|
Market Cap | $30.13B | $42.71B |
Sector | Health | Industrials |
52-Week High | $216.63 | $186.59 |
52-Week Low | $128.93 | $125.61 |
Enterprise Value | $37.20B | $44.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Live Nation (LYV) trades at $185.71, up 0.58% with strong bullish technical signals from moving averages. The stock shows mixed fundamentals with a high P/E of 117.49 but beat Q2 2026 earnings expectations. Revenue growth remains robust at $25.2B in 2025, though net margins are thin at 0.51%. Recent insider sales and legal concerns create headwinds despite analyst optimism.
Outlook remains cautiously optimistic with 87% analyst buy ratings and a $209.54 price target suggesting 13% upside. Key risks include elevated valuation, debt levels, and regulatory scrutiny. The company's dominant live events position and strong demand provide growth catalysts, but execution on cost management will be critical for profitability improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
